More Clinical References for Glucosamine and Chondroitin Safety and Side Effects

Clinical Resources

Reviews of Glucosamine Safety

D’Ambrosio E, Casa B, Bompani R, et al. Glucosamine sulfate: A controlled investigation in arthrosis. Pharmatherapeutica. 1981 ;2:504-508.

Vaz AL. Double-blind clinical evaluation of the relative efficiency of ibuprofen and glucosamine sulfate in the management of osteoarthritis of the knee in out-patients. Curr Med Res Opin. 1982;8:145-149.

Pujalte JM, Llavore EP, Ylescupidez FR. Double-blind clinical evaluation of oral glucosamine sulfate in the basic treatment of osteoarthritis. Curr Med Res Opin. 1980;7:110-114.

Gaulden FC, Keating WC. The effect of intravenous N-acetyl-D-glucosamine on the blood and urine sugar concentrations of normal subjects. Metabolism. 1964;13: 466–472.

Glucosamine Side Effects

McCarty ME The neglect of glucosamine as a treatment for osteoarthritis–A personal perspective. Med Hypotheses. 1994;42:323-327.

Reichelt A, Forster KK, Fischer M, et al. Efficacy and safety of intramuscular glucosamine sulfate in osteoarthritis of the knee. A randomized, placebo-controlled, double-blind study. Arzneim-Forsch DrugRes. 1994;44:75-80.

Weiden S, Wood IJ. The fate of glucosamine hydrochloride injected intravenously in man. J Clin Pathol. 1958;11:343-349.

Levin RM, Krieger NN, Winzer RJ. Glucosamine and acetylglucosamine tolerance in man. J Lab Clin Med. 1961 ;59:927-931.

Chondroitin Sulfate

Deal, CL: “Neutraceuticals as Therapeutic Agents in Osteoarthritis.” Rheumatic Disease Clinics of North America, May 1999; 379-395. Loes M: “Natural Medicine and Pain Relievers: A Review.” Natural Medicine Online .

Chondroitin Sulfate: its in-vitro Effects on Human Articular Chondrocytes Cultivated in Clusters. Bassleer C, Malaise M, University of L B. 3rd, International Congress of the Osteoarthritis Research Society Osteoarthritis in Focus: 5, Suppl A,:69. (1997)

Etude de pnase IV sur action des soses orales del sulfate articulations. Crivelli E, Voy E D. Der informaierte Artz Gazette Medicinale, 3. (1987)

Evaluation of the Chondroitin Sulfate Effects on Chondrocytes’ Cultures Placed in a Pressurization System. Nerucci F, Fioravanti A, Bisogno S, Spinelli G, Marcolongo R. 3rd, International Congress of the Osteoarthritis Research Society Osteoarthritis in Focus: 5, Suppl A,:69, May (1997).

Vérification de l’action de l’acide Chondroitin sulfurique chez des malades arthrosiques. Rovetta G, Monteforte P, Molfetta G, Balestra V. (1972)

Rovetta G (1991): Galactosaminoglycuronoglycan Sulfate (Matrix) in Therapy of Tibiofibular Osteoarthritis of The Knee.drugs Exptl. Clin. Res. XVII (l) 53-57. Weyers W, Iseli D (1987): Pharmakologische Untersuchungen zur antiphalogistische Wirksamkeit Von Chondroitinsulfat. II Mitteilung. Therapiewoche Schweiz, 3, 864.

Effects Of An Oral Chondroprotective Agent (Cosequin) Of Cartilage Metabolism And Canine Serum. McNamara PS, Barr SC, Idouraine A, Lippiello L. Proceedings of the 24th Annual Conference of the Veterinary Orthopedic Society, page 35, 1997.

Evaluation of the Clinical Efficacy of Cosequin in the Treatment of Navicular Syndrome – a Double-Blinded Placebo Controlled Randomized Clinical Trial. Hanson RR, Hammad TA, Brawner WR. World Equine Veterinary Association 5th WEVA Congress Abstracts, 3:3:60, September 1997 and 1997 ACVS Veterinary Symposium Small Animal Proceedings, pages 9-1 0, October 16-19, 1997.

Efficacy and Tolerability of 2 x 400 Mg Oral Chondroitin Sulfate as a Single Dose in the Treatment of Knee Osteoarthritis. Bucci L, Podr G et al. 3rd International Congress of the Osteoarthritis Research Society Osteoarthritis in Focus: 5, Suppl A:69. (1997).

Hematologic, Hemostatic, and Biochemical Effects In Dogs Receiving an Oral Chondroprotective Agent For Thirty Days. McNamara PS, Barr SC, Erb HN. American Journal Veterinary Research, 57: 9:1390-1394, 1996.

Oral Treatment with a Glucosamine-Chondroitin Sulfate Compound For Degenerative Joint Disease In Horses: 25 Cases. Hanson RR, Smalley LR, Huff GK, White S, Hammad TA. Equine Practice, 19:9, October 1997

Results Of A Survey Of Small Animals Practitioners On The Perceived Clinical Efficacy And Safety Of An Oral Chondroprotective Nutraceutical Anderson M, Slater M, Hammad TA. Proceedings of the 24th Annual Conference of the Veterinary Orthopedic Society, page 1, October 1997 and, 1997 ACVS Veterinary Symposium Small Animal Proceedings, page 1, October 16-19, 1997.

Therapeutic Effect Of Cosamin® On Autoimmune Type II Collagen Induced Arthritis In Rats. Baron J, Hill SL, Rose NR. Proceedings of North American Veterinary Conference (Innovations And New Product Applications In Veterinary Practice), page 35, January 1997.

Current Management of Equine Degenerative Joint Diseases (Round Table 6). Turner T, Stone WC, Herthel D, Weinberg C, Leitch M, Markell R. Equine Practice – Roundtable 19:7-8, July/August-September 1997.

Medical therapy of Osteoarthritis in Dogs. Boulay JP, De Angelis M, Kincaid SA, Leeds EB, Prostredny JM, Todhunter RJ. Veterinary Exchange, Roundtable, Supplement to Compendium, published June 1995.

Animal Joint Disease

Roundtable – Degenerative Joint Disease in Dogs. Boothe D, Camp R, Gelfand L, Ross G. Turkell A, Willer R. Canine Practice, 21:1-4 January/February – July/August 1996.

Roundtable on Equine Degenerative Joint Disease White N, Benner E, Grant B, Hanson RR, McNitt D, Mitchell R. Equine Practice, 17:6, June 1995 Soothing Those Sore Joints. Kerwin S, Anderson M, Aronson R, Beale B, Elkins AD, McCarthy R, Sams A. Veterinary Forum – Roundtable on Canine Osteoarthritis, 14:10:55-61, October 1997.

Glucosamine and Condroitin Combined Efficacy

Glycosaminoglycans in the Treatment of Degenerative Joint Disease in Small Animals. Anderson MA, Beaver DP. Emerging Science and Technology 2:3: 38-39, Summer 1996

Oral Glycosaminoglycans in the Treatment of Degenerative Joint Disease in Horses. Hanson RR. Equine Practice, 18:10:18-22, November/December 1996.

Promising Responses To A New Oral Treatment For Degenerative Joint Disorder. Moore MG. Canine Practice, 21:2:7-1 1, March/April 1996.

Slow-Acting, Disease-Modifying Osteoarthritis Agents. McNamara PS, Johnston SA, Todhunter RJ. Veterinary Clinics of North America: Small Animal Practice, 27:4:863-867, 951-952, July 1997.

Schenk RC: “New Approaches to the Treatment of Osteoarthritis: Oral Glucosamine and Chondroitin Sulfate.” AAOS Instructional Course Lectures, Volume 49, 2000; 491-494.

Effects of the Treatment with Matrix on Elderly People with Chronic Articular Degeneration. FA, Cerio R, Grasso A M, Policicchio D, Di Grezia F, Sorrentino P, Lingetti M. Drugs Exptl- Clin. Res. XVII (l) 45-51 (1991).

– – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – –

Be sure to visit the Glucosamine Product Guide for a review of commercially available glucosamine products broken down by 9 different categories such as price per month, quality and type. Learn what the best products out there are and what criteria was used to ranked each.